92976-98-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID is used as a building block for the synthesis of various biologically active molecules for its potential role in creating new drug candidates.
Used in Medicinal Chemistry Research:
(S)-1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID is used as a valuable component in the development of pharmaceutical compounds, contributing to the advancement of medicinal chemistry.
Used in the Treatment of Neurological Disorders:
(S)-1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID is studied for its potential pharmacological properties, particularly for its application in treating neurological disorders, due to its unique structure and properties.
Used as an Antimicrobial Agent:
(S)-1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID is also considered for its antimicrobial properties, making it a candidate for use in applications targeting infectious diseases.

Upstream product

• 93-10-7 quinoline-2-carboxylic acid 
• 46185-24-4 1,2,3,4-tetrahydroquinoline-2-carboxylic acid 
• 63430-79-5 1,2,3,4-tetrahydro-quinoline-2-carboxylic acid methyl ester 

Downstream Products

• 63492-82-0 methyl (2S)-1,2,3,4-tetrahydroquinoline-2-carboxylate 

Relevant academic research and scientific papers

Asymmetric synthesis of chiral heterocyclic amino acids via the alkylation of the Ni(II) complex of glycine and alkyl halides

An investigation into the reactivity profile of alkyl halides has led to the development of a new method for the asymmetric synthesis of chiral heterocyclic amino acids. This protocol involves the asymmetric alkylation of the Ni(II) complex of glycine to form an intermediate, which then decomposes to form a series of valuable chiral amino acids in high yields and with excellent diastereoselectivity. The chiral amino acids underwent a smooth intramolecular cyclization process to afford the valuable chiral heterocyclic amino acids in high yields and enantioselectivities. This result paves the way for the development of a new synthetic method for chiral heterocyclic amino acids.

Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: Synthesis, biological characterization, and behavioral studies

Combination of dopamine D3 antagonism, serotonin 5-HT1A partial agonism, and antagonism at 5-HT2A leads to a novel approach to potent atypical antipsychotics. Exploitation of the original structure-activity relationships resulted in the identification of safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalepsy. The potential atypical antipsychotic 5bb was selected for further pharmacological investigation. The distribution of c-fos positive cells in the ventral striatum confirmed the atypical antipsychotic profile of 5bb in agreement with behavioral rodent studies. 5bb administered orally demonstrated a biphasic effect on the MK801-induced hyperactivity at dose levels not able to induce sedation, catalepsy, or learning impairment in passive avoidance. In microdialysis studies, 5bb increased the dopamine efflux in the medial prefrontal cortex. Thus, 5bb represents a valuable lead for the development of atypical antipsychotics endowed with a unique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophrenia.

Synthesis of new chiral 2-functionalized-1,2,3,4-tetrahydroquinoline derivatives via asymmetric hydrogenation of substituted quinolines

The asymmetric hydrogenation of a series of quinolines substituted by a variety of functionalized groups linked to the C2 carbon atom is providing access to optically enriched 2-functionalized 1,2,3,4-tetrahydroquinolines in the presence of in situ generated catalysts from [Ir(cod)Cl]2, a bisphosphine, and iodine. The enantioselectivity levels were as high as 96% ee.